Orforglipron
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Orforglipron
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken as a once-daily oral pill, representing the first oral GLP-1 agent that does not require food-timing restrictions unlike semaglutide tablets. Phase III trials show approximately 9% weight loss at 36 weeks with a favorable tolerability profile. Developed by Eli Lilly, it may offer broader accessibility due to its oral bioavailability and lack of cold-chain requirements.
Science
Mechanism of Action
Binds the GLP-1 receptor as a small-molecule allosteric agonist, producing appetite suppression, delayed gastric emptying, and enhanced glucose-dependent insulin secretion through the same receptor pathway as peptide GLP-1 analogs but via oral bioavailable formulation.
Dosing
Typical Protocol
3–36 mg oral tablet once daily regardless of food; Phase III dosing titration over 16 weeks.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Orforglipron is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.